DBV Technologies S.A. (DBV) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.236x

Based on the latest financial reports, DBV Technologies S.A. (DBV) has a cash flow conversion efficiency ratio of -0.236x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-49.10 Million ≈ $-57.40 Million USD) by net assets (€207.90 Million ≈ $243.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see DBV market cap for the company's overall valuation and market capitalisation.

DBV Technologies S.A. - Cash Flow Conversion Efficiency Trend (2011–2025)

This chart illustrates how DBV Technologies S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.

DBV Technologies S.A. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of DBV Technologies S.A. ranked by their cash flow conversion efficiency. See DBV Technologies S.A. (DBV) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.

Company Cash Flow Conversion Efficiency
Sparebank 1 Ringerike Hadeland
OL:RING
0.191x
Mengtian Home Group Inc.
SHG:603216
N/A
Xiamen East Asia Machinery Industrial Co. Ltd.
SHE:301028
N/A
ChengDa Pharmaceuticals Co. Ltd.
SHE:301201
N/A
Shenzhen Liande Automatic Equipment Co Ltd
SHE:300545
-0.012x
Empire State Realty Trust Inc
NYSE:ESRT
0.059x
Pantoro Gold Ltd
AU:PNR
0.225x
Nuvectis Pharma Inc
NASDAQ:NVCT
-0.499x

Annual Cash Flow Conversion Efficiency for DBV Technologies S.A. (2011–2025)

The table below shows the annual cash flow conversion efficiency of DBV Technologies S.A. from 2011 to 2025. View DBV share price today for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 €168.79 Million
≈ $197.33 Million
€-126.12 Million
≈ $-147.45 Million
-0.747x +80.41%
2024-12-31 €27.39 Million
≈ $32.02 Million
€-104.47 Million
≈ $-122.14 Million
-3.815x -571.38%
2023-12-31 €140.19 Million
≈ $163.89 Million
€-79.65 Million
≈ $-93.12 Million
-0.568x -98.41%
2022-12-31 €194.50 Million
≈ $227.39 Million
€-55.70 Million
≈ $-65.12 Million
-0.286x +73.74%
2021-12-31 €99.27 Million
≈ $116.06 Million
€-108.24 Million
≈ $-126.55 Million
-1.090x -65.92%
2020-12-31 €252.01 Million
≈ $294.62 Million
€-165.61 Million
≈ $-193.61 Million
-0.657x +12.28%
2019-12-31 €218.05 Million
≈ $254.92 Million
€-163.34 Million
≈ $-190.96 Million
-0.749x +33.50%
2018-12-31 €165.78 Million
≈ $193.81 Million
€-186.74 Million
≈ $-218.32 Million
-1.126x -28.02%
2017-12-31 €182.88 Million
≈ $213.81 Million
€-160.91 Million
≈ $-188.12 Million
-0.880x -258.89%
2016-12-31 €267.90 Million
≈ $313.21 Million
€-65.68 Million
≈ $-76.79 Million
-0.245x -195.04%
2015-12-31 €384.24 Million
≈ $449.21 Million
€-31.93 Million
≈ $-37.33 Million
-0.083x +53.34%
2014-12-31 €182.22 Million
≈ $213.04 Million
€-32.45 Million
≈ $-37.94 Million
-0.178x +45.72%
2013-12-31 €74.09 Million
≈ $86.61 Million
€-24.31 Million
≈ $-28.42 Million
-0.328x -23.20%
2012-12-31 €66.84 Million
≈ $78.15 Million
€-17.80 Million
≈ $-20.81 Million
-0.266x +49.14%
2011-12-31 €19.79 Million
≈ $23.13 Million
€-10.36 Million
≈ $-12.11 Million
-0.524x --

About DBV Technologies S.A.

PA:DBV France Biotechnology
Market Cap
$716.13 Million
€612.54 Million EUR
Market Cap Rank
#10439 Global
#164 in France
Share Price
€2.07
Change (1 day)
-3.63%
52-Week Range
€1.54 - €4.27
All Time High
€83.51
About

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobu… Read more